Alerta

Collaborative artificial intelligence method and system

Resumen de: AU2026205405A1

A method for operating a virtual assistant, the method comprising: at an electronic device: initiating a virtual assistant operable to connect a user with one or more repositories of health information; identifying, by the virtual assistant, the user based on one or more user-specific features; associating a subset of the health information with the user based on the identification of the user, at least a portion of the subset of the health information relating to a particular subject; responsive to receiving a user input via the virtual assistant: accessing, by the virtual assistant, the one or more repositories of information; identifying one or more documents within the one or more repositories as being relevant to the user input; extracting partial response data from the one or more documents; processing, by the virtual assistant, the partial response data in view of the user input to generate a complete response to the user input; and providing the complete response for broadcasting via an output device associated with the electronic device, wherein the steps of identifying one or more documents within the one or more repositories as being relevant to the user input and extracting partial response data from the one or more documents include: identifying at least one parameter in the user input; identifying at least one intent associated with the user input, the at least one intent selected from a pool of intents identified from a plurality of intents based on the at leas

Methods of drug dosing based on early pharmacokinetics

Resumen de: US20260212981A1

0000 Provided is a computer-implemented method for predicting a pharmacokinetic feature for a drug administered to a subject, such as maximum concentration or time to maximum concentration. The method includes: contacting a fluid of the subject with an electrochemical aptamer-based sensor capable of detecting the drug, receiving a series of output values of the electrochemical aptamer-based sensor over a period of time, and using the series of output values to predict the pharmacokinetic feature.

COMPOSITIONS AND METHODS FOR SCREENING 4R TAU TARGETING AGENTS

Resumen de: US20260209296A1

Tau reporter compositions, tau reporter cells, and tau reporter animals are provided that comprise a four-repeat (4R) tau isoform linked to a first reporter protein and a three-repeat (3R) tau isoform linked to a second reporter protein that is different from the first reporter protein. Methods are provided for making such tau reporter cells and tau reporter animals and for using such tau reporter cells and tau reporter animals for assessing the activity of tau-targeting reagents.

COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY

Resumen de: US20260207789A1

0000 The present disclosure relates generally to compositions and methods for determining whether a patient suffers from a traumatic brain injury (TBI) by detecting the presence of an amyloid beta protein in an eye of the patient. Also provided are compositions and methods for preparing a patient for diagnosis and treatment of traumatic brain injury (TB).

PATHOLOGIC TDP-43 AS A BIOMARKER FOR THE DIAGNOSIS OF TDP-43 PROTEINOPATHY

Resumen de: US20260210981A1

Disclosed herein are antibodies or antigen-binding fragments thereof and compositions comprising the same. Also disclosed are methods of detecting TAR DNA-binding protein 43 (TDP-43) in a biological sample, diagnosing a neurodegenerative disease in a subject, and selecting whether to enroll a subject in a clinical trial for frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) using the antibodies or antigen-binding fragments thereof described herein. In addition, disclosed herein are immunoassay kits for selectively detecting TDP-43 in a biological sample.

ANTIBODY COMPOSITIONS TARGETING NON-PHOSPHORYLATED ALPHA-SYNUCLEIN AGGREGATES

Resumen de: US20260209322A1

0000 The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated α-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated α-synuclein and uses thereof. Uses of anti-α-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of α-synuclein-associated neurodegenerative diseases, are also disclosed.

BI-SPECIFIC CHIMERIC ANTIGEN RECEPTOR

Resumen de: US20260209329A1

Aspects of the disclosure relate to polypeptides comprising a signal peptide, an antigen-binding domain that specifically binds TGF-β, a peptide spacer, a transmembrane domain, and an endodomain. When expressed in a cell, the polypeptides are capable of not only neutralizing the TGF-β but also specifically triggering T-cell activation in the presence of TGF-β. T-cell activation spurs the immune cell to produce immunostimulatory cytokines and proliferate, thus turning TGF-β from an immunosuppressive signal to an activating stimulus.

PEPTIDE BIOMARKER

Resumen de: US20260210980A1

The present invention relates to a splice variant of an ICA1 protein that acts as a biomarker for a TDP-43 pathology. In particular, the present invention relates to methods for identifying a splice variant of ICA1 comprising a cryptic peptide sequence, and to related methods of identifying a TDP-43 pathology and/or reduced TDP-43 function in a subject.

METHODS OF TREATING A COGNITIVE IMPAIRMENT

Resumen de: AU2025226972A1

The invention pertains to treating a cognitive impairment, for example, an aging-associated cognitive impairment. In certain aspects, a sample obtained from a subject is assayed for the ratio between the levels of any two proteins selected from: DLL1, SMOC1, CD59, TSTD1, STAT3, POLD4, PARP11, LEFTY2, UNC5B, C5, C5.C6, ASH2L, INHBB, RSP3, VAV3, SIRT3 and SERPINB8. A subject may be having or suspected of having a cognitive impairment. The cognitive impairment can be caused by a neurodegenerative disease, such as Alzheimer's disease. A subject may be identified as likely or not likely to respond positively to the plasma exchange therapy based on the ratio between the levels of measured proteins. In certain aspects, methods for treating a cognitive impairment in the subject comprise administering a plasma exchange therapy comprising a full and/or low volume plasma exchange. Also provided are kits suitable for performing such methods.

METHODS FOR CLASSIFYING, DETECTING AND TREATING BIOLOGICAL DISEASES

Resumen de: AU2024399715A1

The current disclosure provides for methods and compositions for classifying subjects having different biological states. The disclosure describes a method comprising: filtering sequence data obtained from a sample from a subject based on long non-coding RNA (lncRNA) and/or pseudogene RNA (pgRNA), and/or the reference genome; determining a biological state classification of the subject by providing the filtered sequence data to one or more machine learning classifiers as input, wherein the one or more machine learning classifiers is trained to output biological state classifications based on filtered sequence data of a training data set.

B-ISOXAZOLE DERIVATIVES, DIAGNOSTIC COMPOSITIONS; AND METHODS RELATED THERETO

Resumen de: AU2024401251A1

The present application relates to novel b-isox analogs for use in detecting misfolded proteins associated with neurodegenerative diseases, such as ALS, PD, AD, FTLD, and LATE. The present inventors identified and modified a specific site on the b-isox molecule, which significantly enhances detection capabilities. This modification also allows for the selection of analogs that either exhibit low background interference or alter cellular targets, based on the alteration of a functional group at critical site.

BRAWNIN AGONISTS FOR USE IN THE TREATMENT OF AXONAL METABOLIC DISORDERS

Resumen de: US20260210943A1

Using primary mouse neuronal cultures and mouse models, the present inventors have highlighted the role of a new effector, BRAWNIN, in neuronal metabolic balance and cortical axon branching. The present inventors have shown that BRAWNIN expression is necessary and sufficient for cortical axon branching. The present inventors have particularly demonstrated that BRAWNIN expression allows completely restoring impaired axon branching phenotypes in an impaired axon development mouse model. The present invention therefore pertains to a BRAWNIN agonist for use in the treatment of axonal metabolic disorders. The present invention further pertains to screening methods for the identification of novel therapeutic compounds based on BRAWNIN expression in a cellular model.

Single-domain antibodies directed against gasdermin D and their use

Resumen de: US20260209323A1

The present invention is concerned with single-domain antibodies directed against gasdermin D (GSDMD). The single-domain antibodies can be used in medical applications, preferably for preventing and/or treating an inflammatory disease or condition in a subject, and/or for determining the presence or absence of GSDMD oligomers in a sample obtained from a subject.

Organic Electrolyte-Gated Field Effect Transistor Biosensor

Resumen de: US20260210903A1

0000 An organic electrolyte-gated field effect transistor biosensor contains a microfluidic channel structure formed from a dielectric thermoplastic material. A biorecognition entity immobilized within the microfluidic channel allows the biosensor to detect the presence or concentration of an analyte in an electrolyte fluid placed within the channel. The dielectric material separates the microfluidic channel from the gate electrode and from the semiconductor material connecting the drain and source electrodes, and protects the gate electrode and the semiconductor material from direct contact with the electrolyte fluid in the microfluidic channel, to provide the biosensor with a high capacitance. Methods of fabricating the biosensor by monolithic 3D printing are also provided.

METHOD TO DETECT AND TREAT PERIPHERAL NEUROPATHY

Resumen de: US20260210976A1

Disclosed herein is a kit to detect and determine post-synaptic density protein-95 (PSD-95) levels in subjects with peripheral neuropathy. Also disclosed herein, is a method of treating or preventing neuropathy in a subject. The method comprises detecting PSD-95 levels in a sample from the subject, using the kit disclosed herein and when the PSD-95 level differs from a control, the subject is treated for neuropathy.

IMPROVED PEPTIDE INHIBITORS OF P53 BINDING PROTEIN 53BP1

Resumen de: US20260207777A1

0000 Compositions and methods are provided for enhancing homology-directed repair in gene-editing applications using improved inhibitors of 53BP1.

METHODS OF PROGNOSIS FOR HEMORRHAGIC TRANSFORMATION FOLLOWING ENDOVASCULAR TREATMENT

Resumen de: US20260210974A1

Methods are provided for classification, diagnosis, prognosis, theranosis, and/or prediction of an outcome following endovascular treatment (EVT) in an individual suffering from an acute ischemic stroke with respect to development of hemorrhagic transformation (HT). The data and integrated model provided herein demonstrates a pre-operative assessment of single-cell biomarkers for accurate prediction of HT following EVT in individuals suffering from acute ischemic strokes. The integrated model incorporates “immune features” such as activation of signaling proteins and/or the frequency of specific cell subset(s). The analysis and prediction of HT is used to guide therapeutic approaches to EVT and the post-treatment care. Specifically, the level of certain features (e.g. elevated prpS6 in memory Th1 CD4+T cells, elevated pCREB in naïve Th1 CD4+T cells and increased frequency of non-classical monocytes) demonstrate an increased likelihood of HT occurring following EVT.

MULTIPARAMETRIC INTEGRATED MOLECULAR DETECTION OF VIRAL ANTIGENS AND VIRAL NUCLEIC ACIDS

Resumen de: US20260210962A1

0000 Disclosed herein are methods for detecting and treating viral infections. Disclosed is a method of detecting a virus, comprising obtaining a biological sample; capturing a plurality of membranous particles from the biological sample; measuring antigens and nucleic acid levels in the membranous particles or single virions from the biological sample; and measuring an amount of a viral RNA; wherein a virus is detected when the viral protein level or the amount of viral RNA is increased in comparison to a control sample.

HIGH DENSITY MICROARRAYS AND USES THEREOF

Resumen de: US20260210959A1

The present disclosure relates to high density microarrays, methods of manufacturing the arrays, and uses thereof. In particular, the present disclosure provides high density microarrays of biological molecules that allow for specific and sensitive biological assays.

SERUM PEPTIDE PATTERNS FOR DIAGNOSTICS OF ACUTE ISCHEMIC STROKE IN HUMANS AND DIFFERENTIAL DIAGNOSIS OF ACUTE ISCHEMIC STROKE FROM INTRACRANIAL HEMORRHAGIC STROKE

Resumen de: US20260210977A1

The invention relates to 5 serum peptide patterns for diagnostics of acute ischemic stroke (AIS) in humans and differential diagnosis from the intracranial hemorrhagic stroke that are defined using a list of the 100 quantitative peptides that in sera of patients with AIS are increased 2 folds or more as compared with individuals without stroke and patients with intracranial hemorrhagic stroke and a list of 54 qualitative peptides detectable in sera of the patients with AIS but not detectable in the sera of individuals without stroke and in sera of patients with intracranial hemorrhagic stroke.

DIAGNOSIS AND TREATMENT OF LONG-COVID

Resumen de: US20260210975A1

0000 A method of determining a risk of developing a neurological disorder in a Long-COVID patient comprising: (a) testing levels of at least one marker associated with a neurologic disorder in a sample taken from the Long-COVID patient, and (b) making a determination that the Long-COVID patient is at risk of developing said neurological disorder when the levels of said at least one marker is increased in the Long-COVID patient compared to healthy control reference levels of said marker. Also a method of determining a risk of developing a cardiometabolic injury in a Long-COVID patient when the levels of expression of a marker associated to a cardiometabolic injury is different in the Long-COVID patient than the levels of said marker in a healthy control. Also methods of treating Long-COVID with a drug effective to mediate the HIF signaling pathway.

Biomarker Detection Using Layered Receptor and Electrode Configuration

Resumen de: US20260210956A1

0000 Herein disclosed is configuring a layered receptor with at least one layer comprising graphene oxide and an biomarker binding layer configured to bind with a targeted biomarker, connecting a working electrode comprising carbon nanotubes (CNT) and a reference electrode to the layered receptor, and detecting events comprising the targeted biomarker binding layer with the biomarker binding layer, by measuring changes in impedance to a plurality of frequencies of an alternating current voltage signal applied through a patient's body fluid between the working electrode and the reference electrode. The layered receptor may further comprise a plurality of self-assembled layers, comprising, in sequence, a layer abutting the CNT and comprising a polymer and metal nanoparticles, a layer comprising an organosulfur, the graphene oxide layer and the biomarker binding layer. The biomarker binding layer may comprise Syn-211, LB509 or 5G4. The targeted biomarker may be alpha-synuclein. An implementation may report biomarker concentrations in real-time based on detected binding events.

SYSTEMS AND METHODS FOR IDENTIFYING GPCR MODULATORS AND OTHER AGENTS

Resumen de: US20260210961A1

0000 System and methods for identifying agents (e.g., proteins, peptides) that modulate G-protein coupled receptors (GPCRs) are generally described. For some embodiments, the agent is a nanobody that modulates the GPCR and may either act as an agonist (e.g., activate) or antagonist (e.g., deactivate) to the GPCR.

FLUORESCENCE-BASED ASSAY FOR IDENTIFICATION OF PROTAC LIGANDS FOR HECT-TYPE E3 LIGASES

Resumen de: US20260210948A1

0000 A method of identifying a ligand, which is a ligand for a target protein of interest, and which interacts with a homologous to E6AP C-terminus (HECT)-type E3 ligase; a composition comprising (a) a fluorescently labeled peptide comprising a PPxY motif, an E1 ubiquitin (Ub)-activating enzyme, an E2 Ub-conjugating enzyme, a HECT-type E3 ligase, Ub, adenosine triphosphate (ATP), and a reaction buffer or (b) a fluorescently labeled peptide comprising a PPxY motif, a Ub-charged E2 Ub-conjugating enzyme, a HECT-type E3 ligase, ATP, and a reaction buffer; and a composition comprising a ligand identified in accordance with the above method or a pharmaceutically acceptable salt thereof.

GENE THERAPIES FOR LYSOSOMAL DISORDERS

Nº publicación: US20260209718A1 23/07/2026

Solicitante:

PREVAIL THERAPEUTICS INC [US]
PREVAIL THERAPEUTICS, INC.

Resumen de: US20260209718A1

0000 The disclosure relates to compositions and methods for treatment of diseases associated with aberrant lysosomal function, such as fronto-temporal dementia (FTD). The disclosure also provides expression constructs comprising a transgene encoding progranulin or a portion thereof. The disclosure provides methods of treating FTD by administering such expression constructs to a subject in need thereof.